E-Mail
Researchers have uncovered pathways involved in the body s response to glucocorticoid treatments and identified a novel biomarker that could be used to monitor how these drugs work in patients, according to a clinical study published today in
eLife.
A more reliable indicator of an individual s response to glucocorticoid drugs could be used to develop a clinically applicable test that could help tailor treatments and potentially minimise side-effects.
Glucocorticoids, such as cortisol, are a type of hormone with key roles in the body s response to stress. Glucocorticoid drugs are one of the most commonly prescribed treatments for a range of conditions, including for patients whose adrenal glands are unable to produce enough cortisol. The effects of glucocorticoids are complex, meaning the level of cortisol in the blood does not reliably reflect what is happening in the tissues. This makes it hard for medical professionals to know how to tailor treatments.
Lindab och Iver fördjupar samarbetet med transformation till molnet
di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.
EU stoppar vaccindoser till Australien
di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.
Competing for high status speeds up aging in male baboons
elifesciences.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from elifesciences.org Daily Mail and Mail on Sunday newspapers.
E-Mail
BOSTON - New research reveals that when breast cancer cells spread to the brain, they must boost production of fatty acids, the building blocks of fat, in order to survive there. The work, which is published in
Nature Cancer and was led by investigators at Massachusetts General Hospital (MGH) and the Koch Institute of the Massachusetts Institute of Technology (MIT), points to a potential new treatment target for shrinking brain tumors that arise secondary to breast cancer.
Therapies that target the human epidermal growth factor receptor 2 (HER2) have transformed treatment for patients with breast cancer whose tumor cells express HER2, but brain metastases from this disease are typically fatal because they are resistant to anti-cancer therapies that are effective in other locations in the body. This is in part due to the blood-brain barrier that protects the brain against circulating toxins and pathogens, but changes in the cancer cells once they reach the brain may also